scholarly journals Laparoscopic liver resection for locally advanced tumor

2021 ◽  
Vol 25 (1) ◽  
pp. S124-S124
Author(s):  
YOUNGROK CHOI
Keyword(s):  
Liver Resection ◽  
Laparoscopic Liver Resection ◽  
Locally Advanced ◽  
Advanced Tumor ◽  
Locally Advanced Tumor

Thymoma: From Chemotherapy to Targeted Therapy

2012 ◽  
pp. 475-479
Author(s):  
Nicolas Girard
Keyword(s):  
Targeted Therapy ◽  
Personalized Medicine ◽  
Molecular Characterization ◽  
Surgical Resection ◽  
Locally Advanced ◽  
Tumor Burden ◽  
Advanced Tumor ◽  
Druggable Targets ◽  
Locally Advanced Tumor

Overview: Thymic malignancies are rare epithelial tumors that may be aggressive and difficult to treat. Thymomas are frequently eligible for upfront surgical resection. However, nearly 30% of patients present with locally advanced tumor at time of diagnosis, and chemotherapy is then used to reduce the tumor burden—possibly allowing subsequent surgery and/or radiotherapy. Metastatic and recurrent thymic malignancies may be similarly treated with chemotherapy. More recently, the molecular characterization of thymoma led to the identification of potentially druggable targets, laying the foundation to implement personalized medicine for patients.

scholarly journals SURGICAL TREATMENT OF PATIENTS WITH EXTRAORGANIC TUMORS OF THE PELVIC LOCALIZATION WITH INVASION OF THE ILIAC VESSELS

2021 ◽  
pp. 27-30
Author(s):  
I. V. Kryvorotko ◽  
A. V. Chykin ◽  
M. Ye. Tymchenko ◽  
S. O. Beresnyev ◽  
T. Z. Alexandrov
Keyword(s):  
Surgical Treatment ◽  
Surgical Intervention ◽  
Locally Advanced ◽  
Iliac Arteries ◽  
Advanced Tumor ◽  
Pelvic Tumors ◽  
Radical Method ◽  
End To End ◽  
Narrow Space ◽  
Locally Advanced Tumor

The aim of our study was to determine the indications for expanding the scope of operations in patients with pelvic extraorgan local formations. Materials and methods. The results of surgical treatment of 7 patients with nonorgan tumors of the pelvic localization, who underwent resection on the main vessels in connection with their involvement in the tumor process, are presented. Results and discussion. A total of 7 interventions were performed on the iliac arteries — 2 resections with an end-to-end anastomosis and 5 prostheses (one case — the aorta resection with reconstruction with a bifurcation prosthesis). Patients with pelvic extraorgan tumors are a special cohort of patients, due to the presence of several organs in a narrow space, which inevitably causes them to fit snugly to the tumor. Locally advanced tumor process in extraorganic tumors involving the main vessels of the pelvis and adjacent organs is not a reason to refuse surgery, and despite the complications, repeated recurrences and previous operations, are well tolerated by patients. This is especially important due to the lack of a real alternative to surgical treatment of this group of patients. Conclusions. Surgical intervention in the treatment of pelvic inorganic tumors involving the main vessels is the only radical method of treatment. Invasion of the main arterial and venous vessels is not a contraindication to surgery in patients with pelvic tumors. Combined angioplastic interventions allow to achieve a long without recurrent period even after cytoreductive operations.

scholarly journals Prediction of Locally Advanced Urothelial Carcinoma of the Bladder Using Clinical Parameters before Radical Cystectomy - A Prospective Multicenter Study

2015 ◽  
Vol 96 (1) ◽  
pp. 57-64 ◽  
Author(s):  
Thomas Martini ◽  
Atiqullah Aziz ◽  
Florian Roghmann ◽  
Michael Rink ◽  
Felix K. Chun ◽  
...  
Keyword(s):  
Urothelial Carcinoma ◽  
Radical Cystectomy ◽  
Locally Advanced ◽  
Tumor Stage ◽  
Clinicopathological Parameters ◽  
Advanced Tumor Stage ◽  
Advanced Tumor ◽  
Carcinoma Of The Bladder ◽  
Advanced Urothelial Carcinoma ◽  
Locally Advanced Tumor

Introduction: We aimed at developing and validating a pre-cystectomy nomogram for the prediction of locally advanced urothelial carcinoma of the bladder (UCB) using clinicopathological parameters. Materials and Methods: Multicenter data from 337 patients who underwent radical cystectomy (RC) for UCB were prospectively collected and eligible for final analysis. Univariate and multivariate logistic regression models were applied to identify significant predictors of locally advanced tumor stage (pT3/4 and/or pN+) at RC. Internal validation was performed by bootstrapping. The decision curve analysis (DCA) was done to evaluate the clinical value. Results: The distribution of tumor stages pT3/4, pN+ and pT3/4 and/or pN+ at RC was 44.2, 27.6 and 50.4%, respectively. Age (odds ratio (OR) 0.980; p < 0.001), advanced clinical tumor stage (cT3 vs. cTa, cTis, cT1; OR 3.367; p < 0.001), presence of hydronephrosis (OR 1.844; p = 0.043) and advanced tumor stage T3 and/or N+ at CT imaging (OR 4.378; p < 0.001) were independent predictors for pT3/4 and/or pN+ tumor stage. The predictive accuracy of our nomogram for pT3/4 and/or pN+ at RC was 77.5%. DCA for predicting pT3/4 and/or pN+ at RC showed a clinical net benefit across all probability thresholds. Conclusion: We developed a nomogram for the prediction of locally advanced tumor stage pT3/4 and/or pN+ before RC using established clinicopathological parameters.

scholarly journals LOCALLY-ADVANCED SIGMOID CANCER WITH CARCINOMATOSIS AND MULTIPAY RECURRENCES. 15 YEARS OF OBSERVATION

2018 ◽  
pp. 57-62 ◽  
Author(s):  
S. I. Achkasov ◽  
M. S. Likhter ◽  
O. I. Sushkov ◽  
I. V. Nazarov
Keyword(s):  
Colon Cancer ◽  
Local Recurrence ◽  
Life Expectancy ◽  
Treatment Failure ◽  
Clinical Case ◽  
Locally Advanced ◽  
Advanced Tumor ◽  
Aggressive Surgical Approach ◽  
Locally Advanced Tumor ◽  
Sigmoid Cancer

Peritoneal carcinomatosis is a major reason for treatment failure. However, combination of «aggressive» surgical approach with chemotherapy allows achieving good results. In this clinical case, a locally advanced tumor was presented with large carcinomatous node in anomentum. Cytoreductive surgery with a complete cytoreduction in combination with intra-abdominal chemotherapy prevented generalization of carcinomatosis. Subsequently, the patient underwent three surgeries for repeated local recurrence of colon cancer. A 15-year period of observation of the patient suggests that this approach is promising, which significantly increases the length of patients life expectancy.

scholarly journals TREATMENT OF PATIENTS WITH COMPLICATIONS OF COLON CANCER IN CONDITIONS OF MULTIFIELD GERONTOLOGICAL HOSPITAL

2016 ◽  
Vol 175 (3) ◽  
pp. 73-78
Author(s):  
N. I. Glushkov ◽  
T. L. Gorshenin
Keyword(s):  
Colon Cancer ◽  
Laparoscopic Surgery ◽  
Locally Advanced ◽  
Acute Intestinal Obstruction ◽  
Maximal Level ◽  
Treatment Results ◽  
Advanced Tumor ◽  
Tumor Perforation ◽  
Cancer Complications ◽  
Locally Advanced Tumor

The article analyzes treatment results of 482 patients of elderly and senile age with complicated colon cancer forms who were in the hospital for war veterans at the period from 2008 to 2014. The more frequent complication of colon cancer was an acute intestinal obstruction (76,8%). Peritumorous inflammation with abscess formation was noted in 13,5% cases, hemorrhage - in 5,6% tumor perforation - in 4,1% cases. The operations were performed by conventional methods and using endovideosurgical technologies in case of complication of colon cancer. Laparoscopic operations had less volume of intraoperative hemorrhage, lower rate of postoperative complications and reduction of the level of postoperative lethality. The rate of lethality was 31,18% after conventional operations and it consisted of 1,81% after laparoscopic surgery. Total postoperative lethality was 24,5%. The maximal level of postoperative lethality was noted in cases of colon cancer complications and it had an ultimate rate (100%) in cases of perforation of locally advanced tumor.

Recent Strategies for Treating Stage IV Gastric Cancer: Roles of Palliative Gastrectomy, Chemotherapy, and Radiotherapy

2016 ◽  
Vol 25 (1) ◽  
pp. 87-94 ◽  
Author(s):  
Kunihiko Izuishi ◽  
Hirohito Mori
Keyword(s):  
Gastric Cancer ◽  
Performance Status ◽  
Locally Advanced ◽  
Growth Factor Receptor ◽  
Stage Iv ◽  
Stage Iv Gastric Cancer ◽  
Palliative Gastrectomy ◽  
Advanced Tumor ◽  
Esophagogastric Cancer ◽  
Previously Treated

Recently, many strategies have been reported for the effective treatment of gastric cancer. However, the strategy for treating stage IV gastric cancer remains controversial. Conducting a prospective phase III study in stage IV cancer patients is difficult because of heterogeneous performance status, age, and degree of cancer metastasis or extension. Due to poor prognosis, the variance in physical status, and severe symptoms, it is important to determine the optimal strategy for treating each individual stage IV patient. In the past decade, many reports have addressed topics related to stage IV gastric cancer: the 7th Union for International Cancer Control (UICC) TNM staging system has altered its stage IV classification; new chemotherapy regimens have been developed through the randomized ECF for advanced and locally advanced esophagogastric cancer (REAL)-II, S-1 plus cisplatin versus S-1 in RCT in the treatment for stomach cancer (SPIRITS), trastuzumab for gastric cancer (ToGA), ramucirumab monotherapy for previously-treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD), and ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously-treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW) trials; and the survival efficacy of palliative gastrectomy has been denied by the reductive gastrectomy for advanced tumor in three Asian countries (REGATTA) trial. Current strategies for treating stage IV patients can be roughly divided into the following five categories: palliative gastrectomy, chemotherapy, radiotherapy, gastric stent, or bypass. In this article, we review recent publications and guidelines along with above categories in the light of individual symptoms and prognosis. Abbreviations: APC: argon plasma coagulation; AVAGAST: anti-angiogenic antibody bevacizumab, the avastin in gastric cancer; BSC: best supportive care; CF: cisplatin and fluorouracil; CRP: C-reactive protein; DCF: docetaxel, cisplatin, and 5-FU; FISH: fluorescent in-situ hybridization; GJ: gastrojejunostomy; GPS: Glasgow Prognostic Score; HER: human epidermal growth factor receptor; HR: hazard ratio; NLR: neutrophil-to-lymphocyte ratio; OS: overall survival; PS: performance status; QOL: quality of life; RAINBOW: ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously-treated advanced gastric or gastro-oesophageal junction adenocarcinoma; RCTs: randomized controlled trials; REAL: randomized ECF for advanced and locally advanced esophagogastric cancer; REGARD: ramucirumab monotherapy for previously-treated advanced gastric or gastro-oesophageal junction adenocarcinoma; REGATTA: reductive gastrectomy for advanced tumor in three Asian countries; SEER: Surveillance Epidemiology and End Results; SEMS: self-expandable metal stents; SPIRITS: S-1 plus cisplatin versus S-1 in RCT in the treatment for stomach cancer; ToGA: trastuzumab for gastric cancer; TTP: time-to-progression; VEGFR: vascular endothelial growth factor receptor.

scholarly journals Invention of Two Instruments Fitted with SECUREA™ Useful for Laparoscopic Liver Resection

2016 ◽  
Vol 83 (3) ◽  
pp. 107-112 ◽  
Author(s):  
Youichi Kawano ◽  
Nobuhiko Taniai ◽  
Yoshiharu Nakamura ◽  
Satoshi Matsumoto ◽  
Masato Yoshioka ◽  
...  
Keyword(s):  
Liver Resection ◽  
Laparoscopic Liver Resection
Sign in / Sign up

Export Citation Format

Share Document